ClinicalTrials.gg
CompletedNCT05534880Updated Nov 8, 2023

Cybersickness in Different Multisensory Conditions in Virtual Reality

An interventional study of Binaural beats in Cybersickness and Reduced Sensation, sponsored by Federal University of Piaui. Completed at 2 sites in Brazil. Open to participants aged 18 Years to 28 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by Federal University of Piaui · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 28 Years
Sex
All
01

Study summary

Cybersickness (CS) is characterized as a type of visually induced motion sickness, similar to traditional motion sickness, with specific clinical presentations such as dizziness, eyestrain, oculomotor disorders, blurred vision and spatial disorientation. It can be triggered when experiencing virtual reality (VR), and it affects approximately 20% to 80% of individuals who use these resources. Furthermore, the underlying mechanisms of CS are not fully understood and the use of virtual environments that have become increasingly recurrent in several sectors deserves attention, as VR is becoming commonplace in methods and techniques of assessment, diagnosis and treatment. Objective: to analyze cortical electrophysiological activity using electroencephalography (EEG) in individuals with SC, under the influence of different audiovisual conditions. Methodology: The study is a double-blind randomized controlled clinical trial, the sample for survey satisfaction N= 10 participants, the public were university students from the Universidade Federal do Delta Parnaíba (UFDPar) of both sexes, aged between 18 to 28 years, those who agreed, underwent screening, those who met the criteria and fit, were randomized and allocated to one each of 02 conditions, (C1 - video only) and (C2 - associated with binaural audio), three times in each condition, with a duration of 10 minutes of immersion, with evaluation (pre) before (post) with QEEG and Sickness Questionnaire (SSQ), exposure to virtual content was on regular alternate days, with a 24-hour interval between each virtual exposure, at the end of each condition, there will be a 14-day washout and crossover between the conditions. The study will be carried out under all cleaning and prevention care in the fight against the Covid-19 pandemic, data collection will be at the Brain Mapping and Functionality Laboratory (LAMCEF) of the Federal University of Delta do Parnaíba, Piauí, Brazil. Results: The condition with binaural stimulation is expected to promote neuromodulation and reduction of CS symptoms, compared to the control condition.

Read the detailed description

Objectives

General Objective

  • Analyze whether the electrophysiological activity of the brain cortex of individuals with cybersickness undergoes neuromodulation through binaural stimuli;

Specific Objectives

  • Investigate whether stimulation by binaural beats can mitigate the degree of symptoms through the SSQ;
  • Compare whether there is a significant reduction in Sickness Questionare Simulator scores between conditions;
  • Check if there is a difference in absolute power in the Delta band frequency of the parietal and frontal regions between the conditions;

Hypothesis

Our hypothesis is that the condition associated with binaural beats can promote neuromodulation in the electrophysiological activity of the brain cortex, altering the rhythms of brain wave frequencies, which can reduce sensory conflict in cybersickness, through wave entrainment.

02

Conditions studied

  • Cybersickness
  • Reduced Sensation

Browse trials for

Keywords

  • cybersickness
  • virtual reality
  • binaural beats
  • electroencephalography
03

In context

Hypesthesia

47 studies on the registry are indexed under Hypesthesia; 12 are open to participants now.

This study's enrollment of 10 is below the median of 50 across 43 interventional studies indexed under Hypesthesia.

Browse Hypesthesia studies →

Lead sponsor

Federal University of Piaui is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 28 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have normal or corrected to normal vision
  • Participant must have a history of visually induced motion sickness

Exclusion criteria

Exclusion Criteria:

  • Cannot present vestibular disorders
  • Claustrophobia
  • Epileptic seizures
  • Musculoskeletal disorders
  • psychoactive drug use
  • Neurological disorders
  • Considerable hearing loss
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    Virtual Reality

    Condition 01 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video, lasting 10 minutes, there will be 03 sessions on alternate days with a 24-hour interval between each session, before and after each session will be applied the SSQ questionnaire subjective assessment and EEG objective assessment.

    Other: Binaural beats

  • Experimental
    Virtual reality and binaural beats

    Condition 02 - the participants will be induced to CS, they will be immersed in a roller coaster simulation video associated with audio with binaural beat, lasting 10 minutes, there will be 03 sessions on alternate days with a 24-hour interval between each session, before and after each session, the SSQ subjective assessment questionnaire and the objective assessment EEG will be applied.

    Other: Binaural beats

Interventions

  • OtherBinaural beats

    Condition 02- will be used binaural beats, since they are referred through studies with the ability to drive neural oscillations in the beat frequency through differential hemispheric synchronization frequencies, it is expected that a neuromodulation and repercussion of the symptomatological reduction of CS.

06

What researchers measure

Primary outcomes

  1. analysis of electrophysiological activity

    Analisys of absolute power of the Delta band frequencies of the frontal and temporand regions of the brain.

    Time frame: In pre-intervention procedures, the baseline cortical electroencephalography will be analyzed for 5 minutes. After immersion, the same procedures will be performed

Secondary outcomes

  1. Analysis of symptoms through the SSQ questionnaire

    Simulator Sickness Questionnaire (SSQ) is a widely used tool to assess the subjective severity of symptoms of simulator illness and cybersickness. It consists of 16 items, on a four-point scale (from 'none' to 'severe').

    Time frame: In the pre-intervention procedures, before the cortical analysis, the SSQ instrument will be applied, and immediately after each session, the subjective assessment instrument will be applied

07

Study locations

2 sites
  • Federal University of the Delta Parnaíba
    Parnaíba, Piauí 64202-020, Brazil
  • Federal University of the Parnaiba Delta
    Parnaíba, Piauí 64202-020, Brazil
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05534880
Lead sponsor
Federal University of Piaui
Responsible party
Marcos Junio da Costa Silva (Undegraduate, Federal University of Piaui) — Principal investigator
First posted
Sep 10, 2022
Start date
Nov 8, 2022
Primary completion
May 10, 2023
Completion
Jul 9, 2023
Last update
Nov 8, 2023

Study contacts

Victor H. Bastos, Ph. D
principal investigator · Federal University of the Parnaiba Delta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion